Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
← catalyst calendarNCT06430866 · readout in 116 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
163actual
Sites
128
Countries
Argentina, Bulgaria, Chile +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-12 | actual | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Interventions
- Drug: ABP 234
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFArea Under the Serum Concentration-time Curve (AUC) From Time 0 to 21 Days (AUC21d) Following the First Dose
measured 21 days
AUC at Steady State Between Week 16 and Week 19 (AUCtau_ss)
measured Weeks 16-19
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed